GlassScriptPhysician profile
Celeste Ann Wilcox
NPI 1386688232
$736.22
in general payments reported to CMS, 2019-2025
14 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $40.46 · 2021: $182 · 2022: $24.93 · 2023: $50.23 · 2024: $84.00 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $314 · Education: $49.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $314.45 |
| Education | $49.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $151.06 | 2019-2025 | Vyloy |
| Myriad Genetic Laboratories, INC. | $132.40 | 2021 | |
| Abbvie INC. | $108.76 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $91.37 | 2020-2025 | Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $49.20 | 2024-2025 | Fruzaqla |
| Pharmacyclics LLC, An Abbvie Company | $39.87 | 2022-2023 | Epkinly, Imbruvica |
| Novartis Pharmaceuticals Corporation | $37.85 | 2024-2025 | |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Tempus Ai, INC | $23.40 | 2025 | Xt Cdx |
| Genentech USA, INC. | $19.44 | 2025 | Venclexta |
| Daiichi Sankyo INC. | $17.88 | 2024 | Enhertu |
| Array Biopharma INC | $15.21 | 2025 | Mektovi, Xalkori, Lorbrena |
| Acrotech Biopharma INC. | $13.93 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celeste Wilcox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.